Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2010
05/18/2010US7718654 Substituted pteridines for the treatment of inflammatory diseases
05/18/2010US7718648 Pyridobenzazepine compounds and methods for inhibiting mitotic progression
05/18/2010US7718636 Administering to a post menopausal woman an effective amount of 2-methylene -19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3
05/18/2010US7718627 Plasmid comprising nucleotide sequences coding immunoglobulin complementary determining regions specific to tumor antigen (5T4); for use in delivering product and/or nucleotide sequences of interest to tumor; drug delivery
05/18/2010US7718623 Immunostimulatory oligonucleotide that induces interferon alpha
05/18/2010US7718606 Methods for treating muscle diseases and disorders
05/18/2010US7718599 Peptides present in form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts and administration forms also contain one of above acids as free acids; for treating sex hormone-dependent diseases
05/18/2010US7718391 Assays for identifying modulators of rhomboid polypeptides
05/18/2010US7718387 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
05/18/2010US7718379 Identifying haematopoietic stem cells based on cell surface markers
05/18/2010US7718177 Antibodies directed to fragments of connective tissue growth factor (CTGF) polypeptide and methods and uses thereof
05/18/2010US7718166 Immunotherapy for prostate cancer using recombinant bacille Calmette-Guerin expressing prostate specific antigens
05/18/2010CA2472475C 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
05/18/2010CA2465247C Benzimidazoles and analogues and their use as protein kinases inhibitors
05/18/2010CA2438421C Process for the preparation of imidazole compounds
05/18/2010CA2422371C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2422367C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2402193C Novel lhrh-antagonists, production and use thereof as medicament
05/18/2010CA2387536C Rate-controlled particles
05/18/2010CA2382465C Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
05/18/2010CA2378543C Modified human granulocyte-colony stimulating factor and process for producing same
05/18/2010CA2339667C Method of using tetracycline compounds to enhance interleukin-10 production
05/18/2010CA2304204C Quinoline-containing .alpha.-ketoamide cysteine and serine protease inhibitors
05/18/2010CA2302808C 50 human secreted proteins
05/18/2010CA2259143C G-beta-gamma regulated phosphatidylinositol-3' kinase p101 regulatory subunit
05/15/2010CA2739663A1 Polypeptides that bind trail-r1 and trail-r2
05/14/2010WO2010054398A1 Compounds useful as inhibitors of atr kinase
05/14/2010WO2010054397A2 N-cadherin: target for cancer diagnosis and therapy
05/14/2010WO2010054381A2 Method of treating cancer with a combination of a proteasome inhibitor and salubrinal
05/14/2010WO2010054328A2 Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
05/14/2010WO2010054285A2 Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
05/14/2010WO2010054264A1 Use of catecholic butane derivatives in cancer therapy
05/14/2010WO2010054260A1 Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
05/14/2010WO2010054126A2 Small molecule modulators of epigenetic regulation and their therapeutic applications
05/14/2010WO2010054024A2 Novel compounds as cannabinoid receptor ligands
05/14/2010WO2010053877A2 Mhc ii associated protein and uses thereof
05/14/2010WO2010053814A1 Anti-tgf-beta receptor ii antibodies
05/14/2010WO2010053763A1 Tumor-targeting peptides and uses thereof
05/14/2010WO2010053732A1 Isoindoline compounds for use in the treatment of cancer
05/14/2010WO2010053655A2 Therapeutic methods with withaferin a and analogs
05/14/2010WO2010053433A1 Increased expression of specific antigens
05/14/2010WO2010053316A2 New use of sixth immunoglobulin-like domain of vcam-1
05/14/2010WO2010053199A1 Pharmaceutical composition for treating prostate cancer, and method for treating prostate cancer
05/14/2010WO2010053182A1 Kynurenine production inhibitor
05/14/2010WO2010052733A1 NOVEL 4β-AMINO PODOPHVLLOTOXIN CONGENERS AS ANTI TUMOUR ANTIBIOTICS A PROCESS FOR THE PREPARATION THEREOF
05/14/2010WO2010052732A1 Cinnamido-pvrrolor[2,1-c][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
05/14/2010WO2010052580A2 Hsc self-renewal
05/14/2010WO2010052556A1 Treatment with anti-alpha2 integrin antibodies
05/14/2010WO2010052329A1 The use of compounds to inhibit 5a-reductase enzyme activity, and pharmaceutical and cosmetic compositions containing them
05/14/2010WO2010052310A1 Alpha-lipoic acid derivatives and their use in drug preparation
05/14/2010WO2010051935A2 Substituted amido phenoxybenzamides
05/14/2010WO2010051933A2 Substituted sulphonamido phenoxybenzamides
05/14/2010WO2010051781A1 Kinase inhibitors and their use as pharmaceutical agents
05/14/2010WO2010051667A1 Pharmaceutical compositions comprising cyclic peptide nanotubes and the uses thereof
05/14/2010WO2010051664A1 7h-imidazo[1,20-a]pyrano[2,3-c]pyridine derivations and the use thereof
05/14/2010WO2010051639A1 Use of mir-126 for enhancing hematopoietic stem cell engraftment, for isolating hematopoietic stem cells, and for treating and monitoring the treatment of acute myeloid leukemia
05/14/2010WO2010051634A1 Human progenitor t-cells
05/14/2010WO2010033043A8 Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof
05/14/2010WO2010031749A9 Compositions and methods for detecting tlr3
05/14/2010WO2010023473A3 Crystalline form of sunitinib and processes for its preparation
05/14/2010WO2010022089A9 Derivatives of apf and methods of use
05/14/2010WO2010019210A3 Halofuginone analogs for inhibition of trna synthetases and uses thereof
05/14/2010WO2010017443A3 Anti-beta-2-microglobulin agents and the use thereof
05/14/2010WO2010014240A3 Novel bioactive small molecules derived from sea sponges
05/14/2010WO2010011700A3 Treatment of cancers characterized by chromosomal rearrangement of the nut gene
05/14/2010WO2010011599A3 Pimethixene derivatives for promoting bone growth
05/14/2010WO2010009342A3 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
05/14/2010WO2010008876A3 Method for preparation of micellar hybrid nanoparticles for therapeutic and diagnostic applications and compositions thereof
05/14/2010WO2010008528A3 Marek's disease virus vaccine compositions and methods of using thereof
05/14/2010WO2010007531A3 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia
05/14/2010WO2009158526A3 Methods of reducing cellular proliferation by inhibiting acsvl3
05/14/2010WO2009155614A3 A magnetic breather pump and a method for treating a brain tumor using the same
05/14/2010WO2009152167A3 Delivery of therapeutics
05/14/2010WO2009145814A9 Pyrimidines and pyridines useful as inhibitors of protein kinases
05/14/2010WO2009057795A8 Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
05/14/2010WO2009040134A8 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
05/14/2010WO2009033140A9 Microrna signatures in human ovarian cancer
05/14/2010CA2778435A1 Vaccines targeting cellular death receptors
05/14/2010CA2746054A1 Small molecule modulators of epigenetic regulation and their therapeutic applications
05/14/2010CA2743216A1 The use of compounds to inhibit 5a-reductase enzyme activity, and pharmaceutical and cosmetic compositions containing them
05/14/2010CA2743134A1 Compounds useful as inhibitors of atr kinase
05/14/2010CA2743133A1 N-cadherin: target for cancer diagnosis and therapy
05/14/2010CA2743057A1 Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
05/14/2010CA2742991A1 Microrna-mediated regulation of ubc9 expression in cancer cells
05/14/2010CA2742986A1 Use of catecholic butane derivatives in cancer therapy
05/14/2010CA2742961A1 Anti-tgf-beta receptor ii antibodies
05/14/2010CA2742899A1 Treatment with anti-alpha2 integrin antibodies
05/14/2010CA2742622A1 Human progenitor t-cells
05/14/2010CA2741299A1 Isoindoline compounds for use in the treatment of cancer
05/14/2010CA2741047A1 Novel compounds as cannabinoid receptor ligands
05/14/2010CA2733668A1 Monoclonal antibodies to fibroblast growth factor receptor 2
05/13/2010US20100122358 H-Chain-only antibodies
05/13/2010US20100121255 Compound
05/13/2010US20100120909 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
05/13/2010US20100120907 Derivatives of amyris alcohols and eudesmol for treating cold sores and herpes
05/13/2010US20100120901 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
05/13/2010US20100120899 Tumor Repressor Genes in the Prevention of Cancer
05/13/2010US20100120898 MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma
05/13/2010US20100120892 Methods and compositions for the inhibition of stat5 in prostate cancer cells
05/13/2010US20100120891 Use of a galectin-1-targeted rnai-based approach for the treatment of cancer
1 ... 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 ... 2211